@article {1364580,
	title = {Antiangiogenic therapy for ischemic retinopathies},
	journal = {Cold Spring Harb Perspect Med},
	volume = {2},
	number = {6},
	year = {2012},
	month = {2012 Jun},
	pages = {a006411},
	abstract = {Neovascularization is a common pathological process in various retinal vascular disorders including diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal vein occlusion (RVO). The development of neovascular vessels may lead to complications such as vitreous hemorrhage, fibrovascular tissue formation, and traction retinal detachments. Ultimately, irreversible vision loss may result. Various proangiogenic factors are involved in these complex processes. Different antiangiogenic drugs have been formulated in an attempt treat these vascular disorders. One factor that plays a major role in the development of retinal neovascularization is vascular endothelial growth factor (VEGF). Anti-VEGF agents are currently FDA approved for the treatment of AMD and RVO. They are also extensively used as an off-label treatment for diabetic macular edema (DME), proliferative DR, and neovascular glaucoma. However, at this time, the long-term safety of chronic VEGF inhibition has not been extensively evaluated. A large and rapidly expanding body of research on angiogenesis is being conducted at multiple centers across the globe to determine the exact contributions and interactions among a variety of angiogenic factors in an effort to determine the therapeutic potential of antiangiogenic agent in the treatment of a variety of retinal diseases.},
	keywords = {Angiogenesis Inhibitors, Choroidal Neovascularization, Combined Modality Therapy, Diabetic Retinopathy, Glaucoma, Neovascular, Humans, Laser Coagulation, Macular Degeneration, Retinal Neovascularization, Retinal Vein Occlusion, Vascular Endothelial Growth Factor A, Vitrectomy},
	issn = {2157-1422},
	doi = {10.1101/cshperspect.a006411},
	author = {Al-Latayfeh, Motasem and Silva, Paolo S and Sun, Jennifer K and Aiello, Lloyd Paul}
}
